Table 1:
Baseline characteristics and univariate analysis of development of CIN
| All | CIN (n = 7, 8.8%) | No CIN (n = 73, 91.2%) | P Value | |
|---|---|---|---|---|
| Age (yr) | 73.7 | 75.1 | 73.6 | .60 |
| Pre-SCr | 1.11 | 0.99 | 1.12 | .67 |
| Post-SCr | 1.16 | 1.39 | 1.14 | .15 |
| Pre-eGFR | 55.6 | 60.8 | 55.1 | .44 |
| Pre-eGFR <60 | 60.0% | 42.9% | 61.6% | .43 |
| HTN | 71.3% | 85.7% | 69.9% | .67 |
| DM | 37.5% | 14.3% | 39.7% | .25 |
| CAD | 50.0% | 28.6% | 52.1% | .43 |
| Diuretic | 10.0% | 0% | 11.0% | 1.00 |
| Prolonged CSR | 10.0% | 57.1% | 5.5% | .001a |
| Re-administration | 3.4% | 14.3% | 2.7% | .24 |
| Contrast volume | 147.3 mL | 148.6 mL | 147.2 mL | .86 |
| Contrast ratio | 0.57 | 0.49 | 0.58 | .66 |
a
P < .001 on multivariate analysis (OR, 23.0; 95% CI, 3.8–143).